Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
2.5
Journals
Applied Sciences
Special Issues
New Trends in the Development of Pharmaceutical Forms for Human...
applsci-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Applied Sciences Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Trends in the Development of Pharmaceutical Forms for Human and Veterinary Use

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Chemical and Molecular Sciences".

Deadline for manuscript submissions: 30 December 2025 | Viewed by 2430

Special Issue Editors

Dr. Daniel Hernandez-Patlan

E-Mail Website
Guest Editor
Laboratorio 5: LEDEFAR, Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores (FES) Cuautitlán, UNAM, Cuautitlán Izcalli 54740, Mexico
Interests: pharmaceutical and analytical development; poultry science; regulatory affairs
Dr. Bruno Solís-Cruz

E-Mail Website
Guest Editor
Laboratorio 5: LEDEFAR, Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores (FES) Cuautitlán, UNAM, Cuautitlán Izcalli 54740, Mexico
Interests: pharmaceutical development; poultry science; analytical development; regulatory affairs

Special Issue Information

Dear Colleagues,

With technological advances, new trends in the development of conventional and nonconventional pharmaceutical forms for the release of small molecules (drugs, phytobiotics) and large molecules (therapeutic proteins) have emerged, with the aim of treating, preventing, or controlling a wide variety of diseases in humans and animals caused by infectious agents such as viruses, bacteria, and parasites.

This Special Issue therefore aims to feature original research articles and reviews on new trends and/or advances in the development of conventional (capsules, tablets, solutions, emulsions, etc.) and nonconventional (modified-release systems such as tablets, microparticles, and nanoparticles) pharmaceutical forms, as well as their physicochemical characterization during the different stages of development through the use of Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and differential scanning calorimetry (DSC), as well as their evaluation in terms of dissolution and/or release in vitro, stability, and behavior in in vivo models.

Dr. Daniel Hernandez-Patlan
Dr. Bruno Solís-Cruz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • preformulation studies
  • physicochemical aspects of drug product development
  • drug delivery systems
  • biopharmaceutical aspects
  • nanotechnology
  • phytobiotics/natural compounds
  • therapeutic proteins
  • human and animal health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 1810 KiB  
Article
Analysis of Aspirin and Dipyridamole in a Modern Pharmaceutical Formulation-Drug Release Study and Permeability Assessment
by Georgios Kamaris, Nikoletta Pantoudi, Konstantina Chachlioutaki and Catherine K. Markopoulou
Appl. Sci. 2025, 15(11), 6048; https://doi.org/10.3390/app15116048 - 28 May 2025
Viewed by 257
Abstract
Oral administration of dipyridamole (DIP) with acetylsalicylic acid (ACA) is recommended in thromboembolic conditions or for the treatment of myocardial infarction and stroke. The present study presents an alternative dosage form of these two active ingredients, consisting of a honey core and a [...] Read more.
Oral administration of dipyridamole (DIP) with acetylsalicylic acid (ACA) is recommended in thromboembolic conditions or for the treatment of myocardial infarction and stroke. The present study presents an alternative dosage form of these two active ingredients, consisting of a honey core and a dark chocolate coating. The composition masks the bitter taste, is palatable and ensures compliance of a wide range of patients, mainly pediatric. For the simultaneous quantitative determination of the analytes, a Diode Array Detector/Fluorescence Detector (HPLC-DAD/FLD) method was used with a C18 column (250 mm × 4.6 mm, 5 μm) and an isocratic two-phase system (A: H2O 0.2% formic acid—B: Acetonitrile-H2O 90:10 v/v) 65:35 v/v. The method was validated according to ICH guidelines (r2 > 0.999, RSD < 2.3%, % Recovery > 95.4%), and a stability study of the two active ingredients as well as salicylic acid (SAL), which is a hydrolysis product of ACA, was followed. Finally, a digestion protocol (oral cavity–stomach–intestine) for edible materials was applied to determine the release rate of ACA, DIP and SAL in the gastrointestinal tract, while an in vitro permeability study (Papp) was subsequently performed in Franz cells. The results show satisfactory behavior of ACA and DIP and provide a trigger for further studies of the formulation. Full article
(This article belongs to the Special Issue New Trends in the Development of Pharmaceutical Forms for Human and Veterinary Use)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1627 KiB  
Review
Microbiome and Phageome: Key Factors in Host Organism Function and Disease Prevention in the Context of Microbiome Transplants
by Wojciech Jankowski, Małgorzata Mizielińska and Paweł Nawrotek
Appl. Sci. 2025, 15(10), 5330; https://doi.org/10.3390/app15105330 - 10 May 2025
Viewed by 415
Abstract
The study of interactions between gut microbiota and the well-being of the host has become increasingly popular in the last decades. Growing interest in gut microbiota–host interactions has brought attention to faecal microbiota transplantation (FMT) as a clinically effective, though still debated, therapeutic [...] Read more.
The study of interactions between gut microbiota and the well-being of the host has become increasingly popular in the last decades. Growing interest in gut microbiota–host interactions has brought attention to faecal microbiota transplantation (FMT) as a clinically effective, though still debated, therapeutic approach. This review discusses how limitations in the characterisation of gut bacteriomes—particularly interindividual variation and methodological inconsistencies—may influence the outcomes of FMT. The concept of enterotypes is considered as a framework that could support more refined stratification of donors and recipients, offering a possible route toward greater precision in microbiota-based interventions. Further on, the review touches on the subject of interactions among the host, the bacteriome, and the phageome—the community of bacteriophages—with specific focus on the presence and intriguing distribution patterns of crAssviruses. The final chapters are dedicated to discussing the current state of the FMT procedure and its variations, as well as the possibility of performing faecal virome transplants (FVTs) as a potentially safer and equally efficient alternative. Full article
(This article belongs to the Special Issue New Trends in the Development of Pharmaceutical Forms for Human and Veterinary Use)
►▼ Show Figures

Figure 1

24 pages, 1584 KiB  
Review
Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects
by Mariya Dangova, Nadezhda Ivanova and Velichka Andonova
Appl. Sci. 2025, 15(1), 331; https://doi.org/10.3390/app15010331 - 31 Dec 2024
Viewed by 1303
Abstract
A challenge to contemporary medicine is still the discovery of an effective and safe therapy for symptomatic control, if not cure, of Parkinson’s disease. While the potential century’s break-through is sought and foreseen by many scientists in gene therapy, immunotherapy, new drug combinations, [...] Read more.
A challenge to contemporary medicine is still the discovery of an effective and safe therapy for symptomatic control, if not cure, of Parkinson’s disease. While the potential century’s break-through is sought and foreseen by many scientists in gene therapy, immunotherapy, new drug combinations, and neurosurgical approaches, the not-yet-conventional intranasal administration of “classic” levodopa (L-DOPA) also stands out as a perspective from which Parkinson’s patients may benefit in the short term. With the main drawbacks of the standard oral L-DOPA treatment being the extremely low systemic and cerebral bioavailability, it is widely recognized that the nasal route may turn out to be the better administration site, for it offers the alternative of direct brain delivery via the olfactory bulb (the so-called nose-to-brain axis). However, such advancement would be unthinkable without the current progress in nano-scaled drug carriers which are needed to ensure drug stability, mucosal retention and permeation, olfactory uptake, and harmlessness to the sensory neurons and respiratory cilia. This study aims to review the most significant results and achievements in the field of nano-particulate nose-to-brain delivery of L-DOPA. Full article
(This article belongs to the Special Issue New Trends in the Development of Pharmaceutical Forms for Human and Veterinary Use)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop